



Rebiotix Media Contact:  
Jason Rando  
Tiberend Strategic Advisors  
212-375-2665  
jrando@tiberend.com

**Rebiotix’s Phase 3 ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017**

*Data Analyses from Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) Clinical Trials of RBX2660 Focus on Changes in Microbiome Diversity, Universal Donor Findings, and the Lack of Association with Patient Demographics on Treatment Success*

**ROSEVILLE, MN – May 4, 2017** – [Rebiotix Inc.](#), a clinical-stage microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that data analyses from the Phase 2 (PUNCH CD) and Phase 2B (PUNCH CD2) clinical trials of RBX2660 will be the subject of a podium presentation and two poster sessions during Digestive Disease Week (DDW) 2017 being held May 6-9, 2017 in Chicago. RBX2660 is a broad-spectrum microbiota suspension that is designed to rehabilitate the human microbiome by delivering live microbes into a patient’s intestinal tract to treat disease.

Lee Jones, president and CEO of Rebiotix, stated, “We are enthusiastic about the additional insight gleaned from the PUNCH CD and PUNCH CD2 trials of RBX2660 being presented at DDW. Overall, this is a very exciting time for Rebiotix. Based on the results of the Phase 2 program for RBX2660, including our recently announced positive top line data from the open-label Phase 2 study, we look forward to progressing RBX2660 into Phase 3 clinical development, solidifying our position as the most clinically advanced microbiome company in the industry.”

The schedule of Rebiotix-focused presentations at DDW is as follows:

<b>Podium Presentation</b>	<i>Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2, a Randomized Double-Blind Placebo-Controlled Trial</i>
<b>Investigators</b>	Sahil Khanna, MBBS, MS, Gail Hecht, MD, Erik R. Dubberke, MD, MSPH, Robert Orenstein, DO, Christine H. Lee, MD, Dale N. Gerding, MD



**Day & Time** Saturday, May 6<sup>th</sup>, 4:00 PM – 4:15 PM, CT

**Session & Location:** Session 2440; S102abc – McCormick Place

**Poster Presentation:** *Lack of Association with Patient Demographics and Outcomes in PUNCH CD 2, a Randomized Controlled Trial of RBX2660, a Microbiota-Based Drug for Recurrent Clostridium difficile Infection*

**Investigators:** Gail Hecht, Robert Orenstein, Erik R. Dubberke, Christine Lee, Sahil Khanna

**Day & Time:** Tuesday, May 9<sup>th</sup>; 12:00 PM – 2:00 PM, CT

**Session & Location:** Session 9130; South Hall – McCormick Place

**Poster Presentation :** *Donors are Universal in the Fight Against Clostridium difficile: Results from Two Trials Investigating the Safety and Efficacy of RBX2660, a Microbiota-based Drug*

**Investigators:** Arnab Ray, MD, Courtney Jones, BS, Bill Shannon, PhD, MBA , Sharina Carter, BSr

**Day & Time:** Tuesday, May 9<sup>th</sup>; 12:00 PM – 2:00 PM, CT

**Session & Location:** Session 9130; South Hall – McCormick Place

#### **About Rebiotix Inc.**

Rebiotix Inc. is a clinical-stage microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its lead drug candidate, RBX2660, expected to enter Phase 3 clinical development for the prevention of recurrent *Clostridium difficile* (*C. diff*) infection. RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent *C. diff*. infection. Rebiotix's clinical pipeline is also highlighted by RBX7455, a room temperature stable oral capsule formulation, which is currently the subject of a Phase 1 trial for the prevention of recurrent *C. diff*. infection. In addition, Rebiotix is targeting several other disease indications with drug products built on its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit [www.rebiotix.com](http://www.rebiotix.com).